Search Results for "Diabetes"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Diabetes. Results 351 to 360 of 385 total matches.

Sacubitril/Valsartan (Entresto) for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015  (Issue 1474)
in patients with renal impairment, diabetes, or hypoaldosteronism. Worsening of renal function and acute ...
The FDA has approved Entresto (Novartis), an oral fixed-dose combination of the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan, to reduce the risk of cardiovascular death and heart failure hospitalization in patients with heart failure with reduced ejection fraction. Sacubitril is the first neprilysin inhibitor to become available in the US.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):107-9 |  Show IntroductionHide Introduction

Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025  (Issue 1737)
that occur in patients with burns, diabetes, or traumatic or surgical wound infections, are often ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSIs), and community-acquired bacterial pneumonia (CABP) (see Table 1). It is the second cephalosporin with activity against methicillin-resistant S. aureus (MRSA) to be approved in the US; ceftaroline (Teflaro), which was approved for treatment of ABSSSIs and CABP in 2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52   doi:10.58347/tml.2025.1737d |  Show IntroductionHide Introduction

Drugs for HIV Infection

   
Treatment Guidelines from The Medical Letter • Feb 01, 2014  (Issue 138)
resistance/diabetes; retinal changes; optic neuritis indinavir and atazanavir Emtricitabine Well tolerated ...
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are available.
Treat Guidel Med Lett. 2014 Feb;12(138):7-16 |  Show IntroductionHide Introduction

Drugs for Stable Angina Pectoris

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 1994  (Issue 937)
, depression, cold extremities, impotence, constipation, and vivid dreams can occur. In diabetic patients who ...
Many nitrates, beta-blockers, and calcium-channel blockers have now been approved by the US Food and Drug Administration for treatment of stable angina pectoris. The table beginning on page 112 lists the individual drugs, their dosage, and their cost.
Med Lett Drugs Ther. 1994 Dec 9;36(937):111-4 |  Show IntroductionHide Introduction

Vitamin Supplements

   
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005  (Issue 1213)
trial in more than 9000 patients with vascular disease or diabetes found that longer term ...
Many patients ask their physicians whether they should take vitamins. Since the last Medical Letter article on this subject, more data have become available on the benefits and risks of taking vitamin supplements.
Med Lett Drugs Ther. 2005 Jul 18;47(1213):57-8 |  Show IntroductionHide Introduction

Omadacycline (Nuzyra) - A New Tetracycline Antibiotic

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
in Table 4. Complicated ABSSSIs, such as those that occur in patients with burns, diabetes, or traumatic ...
The FDA has approved omadacycline (Nuzyra – Paratek), a semisynthetic tetracycline derivative, for once-daily IV and oral treatment of community-acquired bacterial pneumonia (CAP) and acute bacterial skin and skin structure infections (ABSSSIs) in adults.
Med Lett Drugs Ther. 2019 May 20;61(1572):74-7 |  Show IntroductionHide Introduction

Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
conditions include alcohol use disorder, chronic heart, liver, or lung disease, and diabetes mellitus. 190 ...
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years...
Med Lett Drugs Ther. 2021 Nov 29;63(1638):188-90 |  Show IntroductionHide Introduction

Safety of Aggressive Statin Therapy

   
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004  (Issue 1196)
, female gender, small frame, renal or hepatic dysfunction, diabetes, polypharmacy, perioperative period ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 |  Show IntroductionHide Introduction

Comparison Table: Some Oral/Transdermal Opioid Analgesics (online only)

   
The Medical Letter on Drugs and Therapeutics • Dec 12, 2022  (Issue 1665)
such as diabetes Pregnancy and Lactation Should not be used by breastfeeding women; increased risk ...
View the Comparison Table: Some Oral/Transdermal Opioid Analgesics
Med Lett Drugs Ther. 2022 Dec 12;64(1665):e199-202 |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
Immunocompromising   3 10 X11,12 X11,12 13 14 RF RF 15 conditions8,9 (except HIV) Diabetes   16 10 ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction